<div class="table-responsive">
    <table class="table table-striped table-hover">
        <thead>
            <tr>
                
                <th scope="col">
                    <a href="?cresstrial=12160&amp;modal=1&amp;valnames=arms&amp;order=created_at">Created at</a>
                </th>
                <th scope="col">Source</th>
                
                <th scope="col">Raw Value</th>
                <th scope="col">Validated value</th>
            </tr>
        </thead>
        <tbody>
            
            <tr class="histvalue-row" histvalueid="418505" class="table-">
                
                <td>July 7, 2022, 1:30 p.m.</td>
                <td>oms</td>
                
                <td class="histvalue-container">
                    

        <p class="arms">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;gamma-Globulins;Immunoglobulins;Infusions; Intravenous;Anti-SARS-COV-2 gamma globulin;Group A (Control): Cuban national action protocol for Covid-19. Version 1.6. (Except itolizumab); for seriously patients.Group B (Experimental): Anti-SARS-COV-2 gammaglobulin + Cuban national action protocol for Covid-19. Version 1.6. (Except itolizumab); for seriously patients. This group will receive the investigation product Anti-SARS-COV-2 gammaglobulin; a single dose of 150 mg/kg (1100 IU/Kg) diluted in 300 mL of 0.9 % saline solution (total volume); slow drip initially (20 drops/min) and after 15 min; move to a faster drip; infusing the product in a period of no less than 2 hours; (intravenous route).&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group A (Control): Cuban national action protocol for Covid-19. Version 1.6. (Except itolizumab); for seriously patients.&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group B (Experimental): Anti-SARS-COV-2 gammaglobulin + Cuban national action protocol for Covid-19. Version 1.6. (Except itolizumab); for seriously patients. This group will receive the investigation product Anti-SARS-COV-2 gammaglobulin; a single dose of 150 mg/kg (1100 IU/Kg) diluted in 300 mL of 0.9 % saline solution (total volume); slow drip initially (20 drops/min) and after 15 min; move to a faster drip; infusing the product in a period of no less than 2 hours; (intravenous route).&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}]
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="arms validated">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: 537, &quot;treatment_name&quot;: &quot;Gammaglobulin&quot;, &quot;treatment_type&quot;: &quot;Advanced therapy medicinal products (atmp)&quot;, &quot;pharmacological_treatment&quot;: &quot;Biological treatment&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: 2188, &quot;treatment_name&quot;: &quot;Standard of care&quot;, &quot;treatment_type&quot;: &quot;Standard of care&quot;, &quot;pharmacological_treatment&quot;: &quot;Standard of care&quot;}]
        </p>
        
    
                </td>
            </tr>
            
            <tr class="histvalue-row" histvalueid="415209" class="table-">
                
                <td>June 23, 2022, 2 p.m.</td>
                <td>oms</td>
                
                <td class="histvalue-container">
                    

        <p class="arms">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group A (Control): Cuban national action protocol for Covid-19. Version 1.6. (Except itolizumab); for seriously patients.Group B (Experimental): Anti-SARS-COV-2 gammaglobulin + Cuban national action protocol for Covid-19. Version 1.6. (Except itolizumab); for seriously patients. This group will receive the investigation product Anti-SARS-COV-2 gammaglobulin; a single dose of 150 mg/kg (1100 IU/Kg) diluted in 300 mL of 0.9 % saline solution (total volume); slow drip initially (20 drops/min) and after 15 min; move to a faster drip; infusing the product in a period of no less than 2 hours; (intravenous route).;gamma-Globulins;Immunoglobulins;Infusions; Intravenous;Anti-SARS-COV-2 gamma globulin&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group A (Control): Cuban national action protocol for Covid-19. Version 1.6. (Except itolizumab); for seriously patients.&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group B (Experimental): Anti-SARS-COV-2 gammaglobulin + Cuban national action protocol for Covid-19. Version 1.6. (Except itolizumab); for seriously patients. This group will receive the investigation product Anti-SARS-COV-2 gammaglobulin; a single dose of 150 mg/kg (1100 IU/Kg) diluted in 300 mL of 0.9 % saline solution (total volume); slow drip initially (20 drops/min) and after 15 min; move to a faster drip; infusing the product in a period of no less than 2 hours; (intravenous route).;gamma-Globulins;Immunoglobulins;Infusions; Intravenous;Anti-SARS-COV-2 gamma globulin&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}]
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="arms validated">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: 2188, &quot;treatment_name&quot;: &quot;Standard of care&quot;, &quot;treatment_type&quot;: &quot;Standard of care&quot;, &quot;pharmacological_treatment&quot;: &quot;Standard of care&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: 537, &quot;treatment_name&quot;: &quot;Gammaglobulin&quot;, &quot;treatment_type&quot;: &quot;Advanced therapy medicinal products (atmp)&quot;, &quot;pharmacological_treatment&quot;: &quot;Biological treatment&quot;}, {&quot;arm_notes&quot;: &quot;no third arm&quot;, &quot;treatment_id&quot;: 2188, &quot;treatment_name&quot;: &quot;Standard of care&quot;, &quot;treatment_type&quot;: &quot;Standard of care&quot;, &quot;pharmacological_treatment&quot;: &quot;Standard of care&quot;}]
        </p>
        
    
                </td>
            </tr>
            
            <tr class="histvalue-row" histvalueid="414299" class="table-">
                
                <td>June 17, 2022, 12:30 p.m.</td>
                <td>oms</td>
                
                <td class="histvalue-container">
                    

        <p class="arms">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Anti-SARS-COV-2 gamma globulin;Infusions; Intravenous;Immunoglobulins;gamma-Globulins;Group A (Control): Cuban national action protocol for Covid-19. Version 1.6. (Except itolizumab); for seriously patients.Group B (Experimental): Anti-SARS-COV-2 gammaglobulin + Cuban national action protocol for Covid-19. Version 1.6. (Except itolizumab); for seriously patients. This group will receive the investigation product Anti-SARS-COV-2 gammaglobulin; a single dose of 150 mg/kg (1100 IU/Kg) diluted in 300 mL of 0.9 % saline solution (total volume); slow drip initially (20 drops/min) and after 15 min; move to a faster drip; infusing the product in a period of no less than 2 hours; (intravenous route).&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group A (Control): Cuban national action protocol for Covid-19. Version 1.6. (Except itolizumab); for seriously patients.&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group B (Experimental): Anti-SARS-COV-2 gammaglobulin + Cuban national action protocol for Covid-19. Version 1.6. (Except itolizumab); for seriously patients. This group will receive the investigation product Anti-SARS-COV-2 gammaglobulin; a single dose of 150 mg/kg (1100 IU/Kg) diluted in 300 mL of 0.9 % saline solution (total volume); slow drip initially (20 drops/min) and after 15 min; move to a faster drip; infusing the product in a period of no less than 2 hours; (intravenous route).&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}]
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="arms validated">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: 99, &quot;treatment_name&quot;: &quot;Anti-sars-cov-2 gamma globulin&quot;, &quot;treatment_type&quot;: &quot;Immunoglobulins sars-cov-2 specific&quot;, &quot;pharmacological_treatment&quot;: &quot;Pharmacological treatment&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: 2188, &quot;treatment_name&quot;: &quot;Standard of care&quot;, &quot;treatment_type&quot;: &quot;Standard of care&quot;, &quot;pharmacological_treatment&quot;: &quot;Standard of care&quot;}]
        </p>
        
    
                </td>
            </tr>
            
            <tr class="histvalue-row" histvalueid="296104" class="table-">
                
                <td>March 17, 2022, 5 p.m.</td>
                <td>oms</td>
                
                <td class="histvalue-container">
                    

        <p class="arms">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group A (Control): Cuban national action protocol for Covid-19. Version 1.6. (Except itolizumab); for seriously patients.Group B (Experimental): Anti-SARS-COV-2 gammaglobulin + Cuban national action protocol for Covid-19. Version 1.6. (Except itolizumab); for seriously patients. This group will receive the investigation product Anti-SARS-COV-2 gammaglobulin; a single dose of 150 mg/kg (1100 IU/Kg) diluted in 300 mL of 0.9 % saline solution (total volume); slow drip initially (20 drops/min) and after 15 min; move to a faster drip; infusing the product in a period of no less than 2 hours; (intravenous route).;gamma-Globulins;Immunoglobulins;Infusions; Intravenous;Anti-SARS-COV-2 gamma globulin&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group A (Control): Cuban national action protocol for Covid-19. Version 1.6. (Except itolizumab); for seriously patients.&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group B (Experimental): Anti-SARS-COV-2 gammaglobulin + Cuban national action protocol for Covid-19. Version 1.6. (Except itolizumab); for seriously patients. This group will receive the investigation product Anti-SARS-COV-2 gammaglobulin; a single dose of 150 mg/kg (1100 IU/Kg) diluted in 300 mL of 0.9 % saline solution (total volume); slow drip initially (20 drops/min) and after 15 min; move to a faster drip; infusing the product in a period of no less than 2 hours; (intravenous route).;gamma-Globulins;Immunoglobulins;Infusions; Intravenous;Anti-SARS-COV-2 gamma globulin&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}]
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="arms validated">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: 99, &quot;treatment_name&quot;: &quot;Anti-sars-cov-2 gamma globulin&quot;, &quot;treatment_type&quot;: &quot;Immunoglobulins sars-cov-2 specific&quot;, &quot;pharmacological_treatment&quot;: &quot;Pharmacological treatment&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: 2188, &quot;treatment_name&quot;: &quot;Standard of care&quot;, &quot;treatment_type&quot;: &quot;Standard of care&quot;, &quot;pharmacological_treatment&quot;: &quot;Standard of care&quot;}]
        </p>
        
    
                </td>
            </tr>
            
            <tr class="histvalue-row" histvalueid="295888" class="table-">
                
                <td>March 11, 2022, 3:30 p.m.</td>
                <td>oms</td>
                
                <td class="histvalue-container">
                    

        <p class="arms">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Anti-SARS-COV-2 gamma globulin;Infusions; Intravenous;Immunoglobulins;gamma-Globulins;Group A (Control): Cuban national action protocol for Covid-19. Version 1.6. (Except itolizumab); for seriously patients.Group B (Experimental): Anti-SARS-COV-2 gammaglobulin + Cuban national action protocol for Covid-19. Version 1.6. (Except itolizumab); for seriously patients. This group will receive the investigation product Anti-SARS-COV-2 gammaglobulin; a single dose of 150 mg/kg (1100 IU/Kg) diluted in 300 mL of 0.9 % saline solution (total volume); slow drip initially (20 drops/min) and after 15 min; move to a faster drip; infusing the product in a period of no less than 2 hours; (intravenous route).&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group A (Control): Cuban national action protocol for Covid-19. Version 1.6. (Except itolizumab); for seriously patients.&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group B (Experimental): Anti-SARS-COV-2 gammaglobulin + Cuban national action protocol for Covid-19. Version 1.6. (Except itolizumab); for seriously patients. This group will receive the investigation product Anti-SARS-COV-2 gammaglobulin; a single dose of 150 mg/kg (1100 IU/Kg) diluted in 300 mL of 0.9 % saline solution (total volume); slow drip initially (20 drops/min) and after 15 min; move to a faster drip; infusing the product in a period of no less than 2 hours; (intravenous route).&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}]
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="arms validated">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: 99, &quot;treatment_name&quot;: &quot;Anti-sars-cov-2 gamma globulin&quot;, &quot;treatment_type&quot;: &quot;Immunoglobulins sars-cov-2 specific&quot;, &quot;pharmacological_treatment&quot;: &quot;Pharmacological treatment&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: 2188, &quot;treatment_name&quot;: &quot;Standard of care&quot;, &quot;treatment_type&quot;: &quot;Standard of care&quot;, &quot;pharmacological_treatment&quot;: &quot;Standard of care&quot;}]
        </p>
        
    
                </td>
            </tr>
            
            <tr class="histvalue-row" histvalueid="254313" class="table-">
                
                <td>July 16, 2021, 2 p.m.</td>
                <td>oms</td>
                
                <td class="histvalue-container">
                    

        <p class="arms">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group A (Control): Cuban national action protocol for Covid-19. Version 1.6. (Except itolizumab); for seriously patients.Group B (Experimental): Anti-SARS-COV-2 gammaglobulin + Cuban national action protocol for Covid-19. Version 1.6. (Except itolizumab); for seriously patients. This group will receive the investigation product Anti-SARS-COV-2 gammaglobulin; a single dose of 150 mg/kg (1100 IU/Kg) diluted in 300 mL of 0.9 % saline solution (total volume); slow drip initially (20 drops/min) and after 15 min; move to a faster drip; infusing the product in a period of no less than 2 hours; (intravenous route).;gamma-Globulins;Immunoglobulins;Infusions; Intravenous;Anti-SARS-COV-2 gamma globulin&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group A (Control): Cuban national action protocol for Covid-19. Version 1.6. (Except itolizumab); for seriously patients.&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group B (Experimental): Anti-SARS-COV-2 gammaglobulin + Cuban national action protocol for Covid-19. Version 1.6. (Except itolizumab); for seriously patients. This group will receive the investigation product Anti-SARS-COV-2 gammaglobulin; a single dose of 150 mg/kg (1100 IU/Kg) diluted in 300 mL of 0.9 % saline solution (total volume); slow drip initially (20 drops/min) and after 15 min; move to a faster drip; infusing the product in a period of no less than 2 hours; (intravenous route).;gamma-Globulins;Immunoglobulins;Infusions; Intravenous;Anti-SARS-COV-2 gamma globulin&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}]
        </p>
    

                </td>
                <td class="histvalue-container">
                    

                </td>
            </tr>
            
        </tbody>
    </table>
</div>
Created at	Source	Raw Value	Validated value
July 7, 2022, 1:30 p.m.	oms	[{"arm_notes": "", "treatment_id": null, "treatment_name": "gamma-Globulins;Immunoglobulins;Infusions; Intravenous;Anti-SARS-COV-2 gamma globulin;Group A (Control): Cuban national action protocol for Covid-19. Version 1.6. (Except itolizumab); for seriously patients.Group B (Experimental): Anti-SARS-COV-2 gammaglobulin + Cuban national action protocol for Covid-19. Version 1.6. (Except itolizumab); for seriously patients. This group will receive the investigation product Anti-SARS-COV-2 gammaglobulin; a single dose of 150 mg/kg (1100 IU/Kg) diluted in 300 mL of 0.9 % saline solution (total volume); slow drip initially (20 drops/min) and after 15 min; move to a faster drip; infusing the product in a period of no less than 2 hours; (intravenous route).", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group A (Control): Cuban national action protocol for Covid-19. Version 1.6. (Except itolizumab); for seriously patients.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group B (Experimental): Anti-SARS-COV-2 gammaglobulin + Cuban national action protocol for Covid-19. Version 1.6. (Except itolizumab); for seriously patients. This group will receive the investigation product Anti-SARS-COV-2 gammaglobulin; a single dose of 150 mg/kg (1100 IU/Kg) diluted in 300 mL of 0.9 % saline solution (total volume); slow drip initially (20 drops/min) and after 15 min; move to a faster drip; infusing the product in a period of no less than 2 hours; (intravenous route).", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]	[{"arm_notes": "", "treatment_id": 537, "treatment_name": "Gammaglobulin", "treatment_type": "Advanced therapy medicinal products (atmp)", "pharmacological_treatment": "Biological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]
June 23, 2022, 2 p.m.	oms	[{"arm_notes": "", "treatment_id": null, "treatment_name": "Group A (Control): Cuban national action protocol for Covid-19. Version 1.6. (Except itolizumab); for seriously patients.Group B (Experimental): Anti-SARS-COV-2 gammaglobulin + Cuban national action protocol for Covid-19. Version 1.6. (Except itolizumab); for seriously patients. This group will receive the investigation product Anti-SARS-COV-2 gammaglobulin; a single dose of 150 mg/kg (1100 IU/Kg) diluted in 300 mL of 0.9 % saline solution (total volume); slow drip initially (20 drops/min) and after 15 min; move to a faster drip; infusing the product in a period of no less than 2 hours; (intravenous route).;gamma-Globulins;Immunoglobulins;Infusions; Intravenous;Anti-SARS-COV-2 gamma globulin", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group A (Control): Cuban national action protocol for Covid-19. Version 1.6. (Except itolizumab); for seriously patients.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group B (Experimental): Anti-SARS-COV-2 gammaglobulin + Cuban national action protocol for Covid-19. Version 1.6. (Except itolizumab); for seriously patients. This group will receive the investigation product Anti-SARS-COV-2 gammaglobulin; a single dose of 150 mg/kg (1100 IU/Kg) diluted in 300 mL of 0.9 % saline solution (total volume); slow drip initially (20 drops/min) and after 15 min; move to a faster drip; infusing the product in a period of no less than 2 hours; (intravenous route).;gamma-Globulins;Immunoglobulins;Infusions; Intravenous;Anti-SARS-COV-2 gamma globulin", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]	[{"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}, {"arm_notes": "", "treatment_id": 537, "treatment_name": "Gammaglobulin", "treatment_type": "Advanced therapy medicinal products (atmp)", "pharmacological_treatment": "Biological treatment"}, {"arm_notes": "no third arm", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]
June 17, 2022, 12:30 p.m.	oms	[{"arm_notes": "", "treatment_id": null, "treatment_name": "Anti-SARS-COV-2 gamma globulin;Infusions; Intravenous;Immunoglobulins;gamma-Globulins;Group A (Control): Cuban national action protocol for Covid-19. Version 1.6. (Except itolizumab); for seriously patients.Group B (Experimental): Anti-SARS-COV-2 gammaglobulin + Cuban national action protocol for Covid-19. Version 1.6. (Except itolizumab); for seriously patients. This group will receive the investigation product Anti-SARS-COV-2 gammaglobulin; a single dose of 150 mg/kg (1100 IU/Kg) diluted in 300 mL of 0.9 % saline solution (total volume); slow drip initially (20 drops/min) and after 15 min; move to a faster drip; infusing the product in a period of no less than 2 hours; (intravenous route).", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group A (Control): Cuban national action protocol for Covid-19. Version 1.6. (Except itolizumab); for seriously patients.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group B (Experimental): Anti-SARS-COV-2 gammaglobulin + Cuban national action protocol for Covid-19. Version 1.6. (Except itolizumab); for seriously patients. This group will receive the investigation product Anti-SARS-COV-2 gammaglobulin; a single dose of 150 mg/kg (1100 IU/Kg) diluted in 300 mL of 0.9 % saline solution (total volume); slow drip initially (20 drops/min) and after 15 min; move to a faster drip; infusing the product in a period of no less than 2 hours; (intravenous route).", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]	[{"arm_notes": "", "treatment_id": 99, "treatment_name": "Anti-sars-cov-2 gamma globulin", "treatment_type": "Immunoglobulins sars-cov-2 specific", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]
March 17, 2022, 5 p.m.	oms	[{"arm_notes": "", "treatment_id": null, "treatment_name": "Group A (Control): Cuban national action protocol for Covid-19. Version 1.6. (Except itolizumab); for seriously patients.Group B (Experimental): Anti-SARS-COV-2 gammaglobulin + Cuban national action protocol for Covid-19. Version 1.6. (Except itolizumab); for seriously patients. This group will receive the investigation product Anti-SARS-COV-2 gammaglobulin; a single dose of 150 mg/kg (1100 IU/Kg) diluted in 300 mL of 0.9 % saline solution (total volume); slow drip initially (20 drops/min) and after 15 min; move to a faster drip; infusing the product in a period of no less than 2 hours; (intravenous route).;gamma-Globulins;Immunoglobulins;Infusions; Intravenous;Anti-SARS-COV-2 gamma globulin", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group A (Control): Cuban national action protocol for Covid-19. Version 1.6. (Except itolizumab); for seriously patients.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group B (Experimental): Anti-SARS-COV-2 gammaglobulin + Cuban national action protocol for Covid-19. Version 1.6. (Except itolizumab); for seriously patients. This group will receive the investigation product Anti-SARS-COV-2 gammaglobulin; a single dose of 150 mg/kg (1100 IU/Kg) diluted in 300 mL of 0.9 % saline solution (total volume); slow drip initially (20 drops/min) and after 15 min; move to a faster drip; infusing the product in a period of no less than 2 hours; (intravenous route).;gamma-Globulins;Immunoglobulins;Infusions; Intravenous;Anti-SARS-COV-2 gamma globulin", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]	[{"arm_notes": "", "treatment_id": 99, "treatment_name": "Anti-sars-cov-2 gamma globulin", "treatment_type": "Immunoglobulins sars-cov-2 specific", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]
March 11, 2022, 3:30 p.m.	oms	[{"arm_notes": "", "treatment_id": null, "treatment_name": "Anti-SARS-COV-2 gamma globulin;Infusions; Intravenous;Immunoglobulins;gamma-Globulins;Group A (Control): Cuban national action protocol for Covid-19. Version 1.6. (Except itolizumab); for seriously patients.Group B (Experimental): Anti-SARS-COV-2 gammaglobulin + Cuban national action protocol for Covid-19. Version 1.6. (Except itolizumab); for seriously patients. This group will receive the investigation product Anti-SARS-COV-2 gammaglobulin; a single dose of 150 mg/kg (1100 IU/Kg) diluted in 300 mL of 0.9 % saline solution (total volume); slow drip initially (20 drops/min) and after 15 min; move to a faster drip; infusing the product in a period of no less than 2 hours; (intravenous route).", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group A (Control): Cuban national action protocol for Covid-19. Version 1.6. (Except itolizumab); for seriously patients.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group B (Experimental): Anti-SARS-COV-2 gammaglobulin + Cuban national action protocol for Covid-19. Version 1.6. (Except itolizumab); for seriously patients. This group will receive the investigation product Anti-SARS-COV-2 gammaglobulin; a single dose of 150 mg/kg (1100 IU/Kg) diluted in 300 mL of 0.9 % saline solution (total volume); slow drip initially (20 drops/min) and after 15 min; move to a faster drip; infusing the product in a period of no less than 2 hours; (intravenous route).", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]	[{"arm_notes": "", "treatment_id": 99, "treatment_name": "Anti-sars-cov-2 gamma globulin", "treatment_type": "Immunoglobulins sars-cov-2 specific", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]
July 16, 2021, 2 p.m.	oms	[{"arm_notes": "", "treatment_id": null, "treatment_name": "Group A (Control): Cuban national action protocol for Covid-19. Version 1.6. (Except itolizumab); for seriously patients.Group B (Experimental): Anti-SARS-COV-2 gammaglobulin + Cuban national action protocol for Covid-19. Version 1.6. (Except itolizumab); for seriously patients. This group will receive the investigation product Anti-SARS-COV-2 gammaglobulin; a single dose of 150 mg/kg (1100 IU/Kg) diluted in 300 mL of 0.9 % saline solution (total volume); slow drip initially (20 drops/min) and after 15 min; move to a faster drip; infusing the product in a period of no less than 2 hours; (intravenous route).;gamma-Globulins;Immunoglobulins;Infusions; Intravenous;Anti-SARS-COV-2 gamma globulin", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group A (Control): Cuban national action protocol for Covid-19. Version 1.6. (Except itolizumab); for seriously patients.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group B (Experimental): Anti-SARS-COV-2 gammaglobulin + Cuban national action protocol for Covid-19. Version 1.6. (Except itolizumab); for seriously patients. This group will receive the investigation product Anti-SARS-COV-2 gammaglobulin; a single dose of 150 mg/kg (1100 IU/Kg) diluted in 300 mL of 0.9 % saline solution (total volume); slow drip initially (20 drops/min) and after 15 min; move to a faster drip; infusing the product in a period of no less than 2 hours; (intravenous route).;gamma-Globulins;Immunoglobulins;Infusions; Intravenous;Anti-SARS-COV-2 gamma globulin", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]